PROVIDENCE – Rhode Island Hospital researchers are seeking subjects for a Phase 2 study into whether an investigational drug, Troriluzole, a new version of an ALS-slowing drug, can slow and reverse cognitive decline in Alzheimer’s patients, particularly those with moderate dementia. The Phase 2 study, called T2 Protect AD, evaluates whether Troriluzole can protect against,…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.